What Causes Thrombocytopenia?

Thrombocytopenia—the medical term for a low platelet count—is a common hematologic finding that can arise from numerous underlying causes. Platelets, or thrombocytes, are small anucleate cell fragments essential for hemostasis; a normal count ranges from 150,000 to 450,000 per microliter of blood. Clinically significant thrombocytopenia is generally defined as a platelet count below 150,000/µL, with increased bleeding risk becoming more pronounced below 50,000/µL and spontaneous hemorrhage possible below 10,000/µL.

The etiology of thrombocytopenia falls broadly into three mechanistic categories: decreased platelet production, increased platelet destruction or consumption, and abnormal platelet distribution (e.g., sequestration). Decreased production most commonly stems from bone marrow disorders—including aplastic anemia, myelodysplastic syndromes, leukemia, lymphoma, or metastatic solid tumors—as well as nutritional deficiencies (e.g., vitamin B12 or folate deficiency), chemotherapy or radiation exposure, and certain viral infections such as HIV or hepatitis C.

Increased peripheral destruction or consumption includes immune-mediated conditions like immune thrombocytopenia (ITP), drug-induced thrombocytopenia (e.g., heparin-induced thrombocytopenia or HIT), systemic lupus erythematosus (SLE), and antiphospholipid syndrome. Non-immune causes include thrombotic microangiopathies (e.g., thrombotic thrombocytopenic purpura [TTP] and hemolytic uremic syndrome [HUS]), disseminated intravascular coagulation (DIC), and severe sepsis.

Abnormal platelet distribution—most notably splenic sequestration—occurs in conditions associated with splenomegaly, such as cirrhosis with portal hypertension, lymphoproliferative disorders, or chronic infections like malaria or kala-azar (visceral leishmaniasis). In these cases, platelets are physically trapped in the enlarged spleen rather than destroyed.

Accurate diagnosis requires a comprehensive evaluation: complete blood count with peripheral blood smear review, assessment of other cytopenias, coagulation studies, liver and renal function tests, serologic testing for autoimmune or infectious triggers, and, when indicated, bone marrow aspiration and biopsy. Management is directed at the underlying cause—ranging from observation in mild, asymptomatic cases to corticosteroids, intravenous immunoglobulin (IVIG), thrombopoietin receptor agonists, or splenectomy in ITP; urgent plasma exchange in TTP; or discontinuation of offending medications in drug-induced cases.